The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Leo Toole brings over 20 years' experience in senior finance roles in Pharmaceuticals, Medical Technology and FMCG sectors. He has held senior finance positions at Procter and Gamble, ResMed and Sublimity Therapeutics. Through positions in multinational companies across Europe and in the venture capital space in the UK and Ireland, he has extensive experience in building finance teams, corporate development, equity and debt financing, public markets, and mergers and acquisitions. Leo is a Business graduate of Trinity College Dublin, Ireland and HEC Liège, Belgium. He also holds an MBA with Distinction from INSEAD in France and Singapore.
Shares very much in demand today so far. Plenty of buying going on at these levels.
And still much cheaper than the 6.1p CF paid in the recent placing. A bargain here.
Agree, anything under Cathal's buys at 6p is a bargain - still very much under the radar for some reason.
Just added as much as I can, right share right time excellent price to get in
Jim... According to Cathal in a recent interview he let slip that jupiter had sold out two weeks ago after the firms borker advised them of that ...Also that invesco had 'committed' to given him 12 months to prove the concept so all things being equal this is PIs driving SP movements at the moment...
Thanks as well.
It is so rare for a chairman to be so explicit as to what the plan is, likelihood and appear to be so dynamic with alot of skin in the game.
Clearly he is a salesman and that maybe putting some off but monetising the company is exactly what should be done with such a technically great co [hVIVO] that was sadly lacking before.
Right person, right company, right plan, right time imo and cheaper than he bought .
Once Jupiter is out, I'm sure this will pop even before contract news - all imo.
cheers for that Shandy.....nice he is confident but not overconfident and ramping :)
Hi, sorry was out most of yesterday with no access to my laptop.
The event was attended by c25 people which i thought was slightly disappointing - room could hold maybe 50.
I've been in ORPH for quite a while now so the presentation was merely a recap for me, although most people in the room appeared to not currently hold (3 companies presented in total) and some questions were quite general in nature e.g. role of ORPH during the vaccine testing i.e. are we at risk if patient has side effects etc. Answer NO.
Cathal did mention Immutex - called it our lottery ticket. Explained that this is currently valued at 0 on books, but clearly could have a great value in future. This flu vaccine would be a once in every 5 year injection so the potential upside is high , but Cathal said ORPH wouldn't be committing any money themselves.
In terms of contracts a couple of more points. He mentioned the Venn part of business should be break even Q1 and HVO Q2, so maybe this is where people have interpreted delays.
He did finish this by saying ONLY invest if we announce a constant flow of contracts so this shows me he must be reasonably confident.
Another question someone asked was around cost cutting etc. Cathal said he wanted ORPH to be more like a law firm with minimal admin staff and most staff fee earners. Personally whilst i agree with this you also need the right people to go out and get new business and sometimes these are different skills. Thought Cathal's answer was a bit vague here - did mention if not breakeven by end of Q2 there would be more cost cutting!!
Hopefully current share price reduction is just a reflection on general market concerns rather than ORPH specific.
Any news on this front
https://www.google.com/amp/s/www.proactiveinvestors.co.uk/companies/amp/news/212301
good of you to update us all.